Literature DB >> 16321893

Somatostatin for Uveitic Cystoid Macular Edema (CME).

Thekla Papadaki1, Ioannis Zacharopoulos, Barbara Iaccheri, Tito Fiore, C Stephen Foster.   

Abstract

PURPOSE: To report the favorable response of bilateral recalcitrant uveitic cystoid macular edema (CME) to treatment with a somatostatin analog.
METHODS: Medical ophthalmic history and the results of ophthalmic examinations were recorded. Fluorescein angiography (FA) studies were reviewed.
RESULTS: A 52-year-old white female with intermediate uveitis developed bilateral recalcitrant CME. Treatment with subcutaneous injections of the somatostatin analog octreotide resulted in partial resolution of the CME and improvement of visual acuity.
CONCLUSIONS: Somatostatin may play a role in the treatment of CME secondary to uveitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16321893     DOI: 10.1080/09273940691001964

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  8 in total

1.  Vitreous levels of somatostatin in patients with chronic uveitic macular oedema.

Authors:  A Fonollosa; E Coronado; R Catalan; M Gutierrez; C Macia; M A Zapata; N Martinez-Alday; R Simo; J Garcia-Arumi
Journal:  Eye (Lond)       Date:  2012-08-10       Impact factor: 3.775

Review 2.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

3.  Comment on: "Autoimmune uveitis: clinical, pathogenetic, and therapeutic features".

Authors:  Gokhan Ozge; Murat Kucukevcilioglu; Mehmet Talay Koylu
Journal:  Clin Exp Med       Date:  2016-04-06       Impact factor: 3.984

Review 4.  Uveitis: advances in understanding of pathogenesis and treatment.

Authors:  Russell W Read
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

5.  Bevacizumab in inflammatory eye disease.

Authors:  McGregor N Lott; Joyce C Schiffman; Janet L Davis
Journal:  Am J Ophthalmol       Date:  2009-08-05       Impact factor: 5.258

6.  Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis.

Authors:  Michal Schaap-Fogler; Radgonde Amer; Ronit Friling; Ethan Priel; Michal Kramer
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-12-24       Impact factor: 3.117

7.  Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema.

Authors:  Alaa E Radwan; Cheryl A Arcinue; Paul Yang; Pichaporn Artornsombudh; Esam M Abu Al-Fadl; C Stephen Foster
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-03-22       Impact factor: 3.117

8.  Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis.

Authors:  Rushmia Karim; Evripidis Sykakis; Susan Lightman; Samantha Fraser-Bell
Journal:  Clin Ophthalmol       Date:  2013-06-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.